Phase 3 Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who have received a kidney transplant from a deceased or living donor, where the donor and recipient are not a full genetic (HLA) match, and where blood types are compatible
- People whose kidney function (measured by a specific calculation called CKD-EPI) is below 30 ml/min/1.73m²
- People currently taking a specific combination of anti-rejection medications known as CNI and MPA, with or without prednisone (a steroid)
- People whose 10-week post-transplant kidney biopsy showed no signs of rejection, no BK virus infection, no disease recurrence, no blood vessel complications, and no tissue death
- People who have previously been exposed to the Epstein-Barr virus (EBV), confirmed by a blood test
- People who are able to understand and communicate with the research team
- People who agree to provide written consent to participate
- People covered by a French Social Security policy
- People with no medical reason preventing a kidney biopsy at 10 weeks after transplant
- People who return a negative pregnancy test and agree to use effective contraception throughout the study
Who may not be able to join:
- People who have developed antibodies specifically targeting their donor's tissue (called Donor Specific Antibodies), either at the time of transplant or within the first 3 months after
- People who are HIV positive
- People who have previously received another solid organ transplant (other than a kidney)
- People whose transplanted kidney never began working and who still require dialysis at 3 months after transplant
- People currently taking part in another interventional clinical trial
- People whose overall health condition the trial doctor considers incompatible with taking part in the study
- People who have a medical reason preventing them from taking the study medications belatacept or tacrolimus
- People who are pregnant or breastfeeding
- People who would be unable to follow the study procedures as required
- People who are under legal guardianship, court protection, or a similar legal arrangement
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0240087453
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Feasibility of a transient replacement of CNIs by belatacept in renal transplant patients with early graft dysfunction. Creatinine clearance did not decrease by more than 25% from the cessation of belatacept 6 months after reintroduction of CNI.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.